Drug
Tralokinumab
Tralokinumab: highest development phase Phase 3, developed by LEO Pharma. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tralokinumab NCT03587805 | Phase 3 | Atopic Dermatitis |
| Tralokinumab NCT03363854 | Phase 3 | Atopic Dermatitis |
| Tralokinumab NCT05958407 | Phase 3 | Atopic Dermatitis |
| Tralokinumab NCT05388760 | Phase 2 | Atopic Dermatitis |
| Tralokinumab NCT03556592 | Phase 1 | Atopic Dermatitis |
Latest
No recent events.
Follow Tralokinumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.